INSIGHTS ON CELL & GENE THERAPY DISCOVERY

• High Efficiency T-Cell Editing

  Explore a modified synthetic sgRNA that allows you to achieve efficient, multigene knockout in primary human resting CD4+ T-Cells.

• Navigating The Complexities Of Engagement Qualifications In Single-Use Assemblies

  In lieu of formal industry guidance for single-use integrators, it’s important to understand engagement testing, as well as review the factors related to the selection of retention device and assembly.

• How Tunable Cell Processing Solutions Ensure Separation Efficiency

  Single-use tubular bowl centrifuges are standing out to cell therapy developers for their ability enable the optimal balance between high separation efficiency, high productivity, and low shear.

• The Shear Problem Facing Cell Separation

  Explore the significance of low-shear separation and delve into the principles of tubular bowl centrifugation, comparing it to alternative technologies.

• Tips For Designing A Single-Use Manifold For Advanced Therapies

  Expert single-use engineers address six common questions posed by cell and gene therapy manufacturers in the design of custom single-use manifolds for the critical handling of biological fluids.

• How Takeda Streamlines Assay Transfer And Troubleshooting

  When one of Takeda’s quality control facilities wanted to improve assay success rates by reducing liquid handling variability, they turned to the Artel MVS® to help their assay process.

• Improving Automated Liquid Handling Performance For Serum-Based Assays

  Here, we highlight the similarities between the serum mimic solution Artel is developing and various commercially available sera as well as the importance of choosing the appropriate liquid classes.

• How CRL Automated Their Assay And Scale Throughput

  Discover how Artel® technology played a critical role in Clinical Reference Labs' exceptionally fast development and scale-up of a saliva-based SARS-CoV-2 assay to meet the unprecedented testing need.

• Discover A Reference Control Alternative To HIV+ Donor Samples

  A Fortune 100 pharmaceutical company found success in addressing their HIV treatment research challenges through a partnership that provided them with a p24-expressing, non-infectious synthetic T cell mimic.

• Navigating The FDA’s Draft Guidance On Psychedelic Drug Development

  Uncover new guidance for the development of innovative therapies in the realm of mental health and addiction treatment.